The size of the North America Alzheimer’s Disease Therapeutics and Diagnostics Market was worth USD 3349 Million in 2020. This value is estimated to be growing at a CAGR of 4.74% to reach USD 4223 Million by 2025.
The growing geriatric population and the increasing ubiquity of Alzheimer's disease are important factors driving Alzheimer's disease therapeutics and diagnostics market in North America. According to the Alzheimer’s Association, in 2016, an estimated 5.4 million Americans of all ages have Alzheimer's disease. One in nine people aged 65 and above has Alzheimer's disease. By 2050, the number of people aged 65 and above affected by Alzheimer's disease is projected to nearly triple, from 5.2 million to an expected 13.8 million. Increasing R&D activity and a strong pipeline of disease-modifying drugs are the crucial factors driving the growth of the market in this region. Alzheimer's disease is the leading cause of dementia in the elderly population, an integral part of the general aging process. Hence, the increasing geriatric population globally acts as a key driver for Alzheimer's disease diagnosis and treatment market. The high prevalence of Alzheimer's disease worldwide acts as a key factor for the growth of the market. It stresses the need to improve a successful cure for Alzheimer's disease.
Additionally, Factors contributing to the market's growth are increasing the development of online drugs, increasing incidence and prevalence of Alzheimer's disease, increasing sophisticated diagnostics for early detection and precise drug development, and new emerging diagnostic techniques. Investments in biomarker development for drug development and early detection of Alzheimer's disease are the main drivers and drive the growth of the North American market for Alzheimer's disease diagnosis and treatment.
The early diagnosis of the indication is a challenge for Alzheimer's disease and is becoming a significant threat to public health due to the growing number of people affected.
This research report on the North America Alzheimer’s disease Diagnostics and Therapeutics Market has been segmented and sub-segmented into the following categories:
Regional Analysis:
North America currently dominates the global market for Alzheimer's disease diagnostics and therapeutics and is expected to continue strengthening for a few years. The United States holds the largest share of the worldwide market for diagnosing and treating Alzheimer's disease. The United States is considered the world leader in the intervention and treatment of Alzheimer's disease. The United States has many biopharmaceutical companies, accumulating 86 drugs to fight Alzheimer's disease at different stages of the process. Hence, the market is expected to display a healthy CAGR during the forecast period. According to the Alzheimer's Association, more than 6 million Americans will be living with Alzheimer's disease by 2020. One in nine people aged 60 and over has Alzheimer's disease. By 2040, the number of people aged 60 and over affected by Alzheimer's disease is expected to nearly triple, from 6.2 million to 17.8 million, excluding the development of medical advances to prevent or cure the disease. Death rates from Alzheimer's disease are relatively high. Between 2005 and 2019, deaths from heart disease, stroke, and prostate cancer decreased by 15%, 24%, and 12%, respectively, while deaths from Alzheimer's disease increased by 76%. The United States accounts for a significant share of approximately 86% of total revenues in North America.
The major companies dominating the Alzheimer’s Disease Therapeutics and Diagnostics market in this region are Abbvie Inc., Pfizer Inc., AC Immune SA, Eisai Co Ltd., Allergan PLC, Novartis AG, Amarantus Bioscience Holdings, H. Lundbeck A/S, Anavex LifeSciences, Avid Radiopharmaceuticals, Forest Laboratories Inc., Axon Neuroscience, Daiichi Sankyo Co, TauRx Therapeutics Ltd, Eli Lilly, F. Hoffmann La Roche AG, Johnson & Johnson, GE Healthcare and Janssen Pharmaceuticals.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Therapeutics
5.1.1 Introduction
5.1.2 Marketed Drugs
5.1.2.1 NMDA Receptor Antagonists
5.1.2.2 Cholinesterase Inhibitors
5.1.3 Pipeline Drugs
5.1.4 Y-o-Y Growth Analysis, By Therapeutics
5.1.5 Market Attractiveness Analysis, By Therapeutics
5.1.6 Market Share Analysis, By Therapeutics
5.2 Diagnostics
5.2.1 Introduction
5.2.2 Computed tomography scan
5.2.3 Electroencephalography
5.2.4 Lumbar puncture test
5.2.5 Magnetic resonance imaging
5.2.6 Positron emission tomography
5.2.7 Others
5.2.8 Y-o-Y Growth Analysis, By Diagnostics
5.2.9 Market Attractiveness Analysis, By Diagnostics
5.2.10 Market Share Analysis, By Diagnostics
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Therapeutics
6.1.3.3 By Diagnostics
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Therapeutics
6.1.4.3 By Diagnostics
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Therapeutics
6.1.5.3 By Diagnostics
6.2 United States
6.3 Canada
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Abbvie Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Pfizer Inc.
8.3 AC Immune SA
8.4 Eisai Co Ltd.
8.5 Allergan PLC
8.6 Novartis AG
8.7 Amarantus Bioscience Holdings
8.8 H. Lundbeck A/S
8.9 Anavex LifeSciencescs
8.10 Avid Radiopharmaceuticals
8.11 Forest Laboratories Inc.
8.12 Axon Neuroscience
8.13 Daiichi Sankyo Co
8.14 TauRx Therapeutics Ltd
8.15 Eli Lilly
8.16 F. Hoffmann La Roche AG
8.17 Johnson & Johnson
8.18 GE Healthcare
8.19 Janssen Pharmaceuticals
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
